神经轴突导向分子Sema3A在卵巢癌中的表达及其临床意义

目的:检测卵巢上皮细胞肿瘤中Sema3A的表达情况,并探讨其与临床病理间的关系,分析Sema3A检测在上皮性卵巢癌诊断中的作用。方法:收集80例卵巢肿瘤石蜡标本,采用免疫组织化学法对不同病理分级的卵巢上皮性肿瘤进行Sema3A检测,并用蛋白印迹法检测Sema3A在另8对新鲜良、恶性卵巢肿瘤组织中的表达变化。结果:免疫组织化学检测结果示,在上皮性卵巢癌(卵巢癌)、上皮性交界性肿瘤(交界性肿瘤)及上皮性良性肿瘤(良性肿瘤)中,Sema3A表达存在差异。卵巢癌中Sema3A的表达与其病理分级(r=-0.624;P<0.001);而不同组织学分类的卵巢癌(浆液性乳头状腺癌、子宫内膜样腺癌、透明细胞癌、黏液样腺癌)间Sema3A的表达亦有显著差异(P<0.05)。8对卵巢上皮性良、恶性肿瘤组织的蛋白印迹检测结果与免疫组织化学检测结果完全相符,卵巢良、恶性肿瘤中的Sema3A表达有显著差异(P<0.001)。结论:Sema3A在卵巢癌、卵巢交界性肿瘤及卵巢良性肿瘤中的表达呈明显递降趋势。卵巢癌中Sema3A的表达水平随肿瘤恶性程度增高而增高,表明Sema3A阳性表达在卵巢癌诊断中有一定价值,并可提示肿瘤的恶性程度。

Expression of Sema3A in ovarian cancer and its clinical significance

Object： To investigate the expression of Sema3A in human epithelial ovarian tumor and the correlation of Sema3A expression with clinicopathological features. Methods： Expressions of Sema3A in 80 paraffin embedded ovarian tumor samples and 8 fresh ovarian tumor specimens were determined by immunohistochemical staining and Western blotting, respectively. The data were analyzed with SPSS 19.0 software package for x2 test. Results： Immunohistochemical findings revealed that the expression of Sema3A differed in ovarian cancer, transitional cell ovarian tumor and benign ovarian tumor. Sema3A expression was correlated significandy with pathologic stage （Spearman＇s r=-0.624, P〈0.001） and histologic subtype （Spearman＇s r=0.311, P〈0.05） of ovarian cancer. Western blotting results of 8 fresh specimens demonstrated similar results. The expression of Sema3A differed significantly between benign ovarian tumor and ovarian cancer （P〈0.001）. Conclusions： Expression level of Sema3A decreases gradually from ovarian cancer, transitional cell ovarian tumor to benign ovarian tumor. Sema3A expression increase with the increase in malignancy degree. Expression of Sema3A has certain value for the diagnosis and malignancy degree estimation of ovarian cancer.